The global pharmaceutical landscape is witnessing a structural transformation as SGLT2 inhibitors evolve from secondary glucose-lowering agents into foundational therapies for multi-organ protection. According to the latest strategic analysis by Fact.MR, the global SGLT2 Inhibitors Market is valued at USD 19 billion in 2026 and is projected to surge to USD 34.6 billion by 2036, expanding...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek